JS004

Phase 2Small molecule

SShanghai Pulmonary Hospital, Shanghai, China

JS004 is one of 101 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

JS004

SShanghai Pulmonary Hospital, Shanghai, China

Phase 2

1 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Toripalimab

NCT06690697

Q2 2027

Phase 1/2Not yet recruiting

Pancreatic Cancer

NCT06370754

Q3 2030

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT05891080

Phase 2Not yet recruiting

Small Cell Lung Cancer

NCT06648200

Q1 2032

Phase 2Recruiting

Small Cell Lung Cancer

NCT06256237

Clinical

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06648200·100 enrolled

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06256237·30 enrolled

Non-Small Cell Lung Cancer1 trial

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT05891080·124 enrolled

Pancreatic Cancer1 trial

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not yet recruiting·FFudan University·Phase 1/2·NCT06370754·117 enrolled

Toripalimab1 trial

Combination of Toripalimab and JS004 Therapy for ccRCC

Recruiting·FFudan University·Phase 2·NCT06690697·80 enrolled

Patients With Advanced Solid Tumors1 trial

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Terminated·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT05427396·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for JS004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JS004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JS004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pulmonary Hospital, Shanghai, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Pulmonary Hospital, Shanghai, China

JS004

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2030

Q1 2032

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Non-Small Cell Lung Cancer1 trial

Pancreatic Cancer1 trial

Toripalimab1 trial

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News